Methadone Market

Methadone Market Size:

The global methadone market size reached US$ 126.6 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 195.6 Million by 2032, exhibiting a growth rate (CAGR) of 4.95% during 2024-2032. The widespread adoption of safer pregnancy management, increasing concerns about the side effects of narcotics drugs, and the increasing number of patients associated with therapeutic pain treatment are some of the major factors propelling the market growth.

Methadone Market Analysis:

• Major Market Drivers: The growing government initiatives to combat the opioid crisis, the increasing awareness and treatment options, and the rising prevalence of opioid addiction are major drivers of the market across the globe. The expanding healthcare infrastructure and support services for addiction treatment, coupled with the rising acceptance and utilization of MAT, is further boosting the demand for methadone in managing opioid dependence.
• Key Market Trends: The widespread adoption of medical-assisted treatment (MAT) programs, increasing integration of digital health technologies for remote monitoring and support of patients, and the rising shift towards more outpatient treatment facilities are the key trends of the market across the globe. The growing focus on comprehensive care, combining methadone treatment with behavioral and counselling therapies.
• Geographical Trends: North America is accounted as the largest region in the methadone market growth. The escalating opioid epidemic, rising awareness and acceptance of medication-assisted treatment (MAT), supportive government policies and the expanding access to addiction treatment programs are driving the growth of the market across the North American region. Efforts to reduce stigma and integrate comprehensive care approaches further propel the market growth.
• Competitive Landscape: Some of the major market players in the methadone industry include Mallinckrodt Pharmaceuticals, Hikma Pharmaceuticals PLC., VistaPharm Inc. (Pharmaceutical Associates Inc.), among many others.
• Challenges and Opportunities: The market faces several challenges including stigma associated with opioid addiction treatment, potential side effects leading to patient noncompliance, and regulatory restrictions. However, the market also faces various opportunities including arise from the increasing prevalence of opioid addiction and increasing acceptance of medication-assisted treatment (MAT). Technological advancements in telemedicine and digital health platforms can enhance patient monitoring and support.
   

Methadone Market Trends:

Rising Prevalence of Opioid

The increasing cases of opioid addiction necessitate effective treatment solutions like methadone to manage withdrawal symptoms and cravings. According to the World Health Organization (WHO), opioid-involved overdose deaths rose from 49,000 860 in 2019 to 81,806 in 2022. Overall, drug overdose deaths rose from 2019 to 2022 with 107941 drug overdose deaths reported in 2022. Drug overdose deaths involving prescription opioids rose from 3440 two 1999 to 17,029 in 2017. From 2017 to 2019, the number of deaths decline to 14,139. This was followed by a slight increase in 2020, with 16,416 reported deaths. In 2022, the number of deaths declined to 14,716. This statistic supports the rising need for effective opioid management measures, which, in turn, is further fueling the methadone market statistics significantly.

Growing Recognition of Medication-Assisted Treatment (MAT)

The increasing acceptance of MAT's effectiveness in treating opioid dependence is boosting the demand for methadone, integrating it into comprehensive care approaches for addiction management. According to an article by Public Health Scotland, medication-assisted treatment standards 125 were assessed across all 29 alcohol and drug partnerships. Of 145 standards of care assessed, 17% (25/145) are fully implemented, 65% (94/145) are partially implemented and 18% (26/145) are not implemented. This suggests walk has stopped or is well established in most alcohol and drug partnership areas but that there is still a lot to do hopeful, consistent, and sustained implementation of the standards across Scotland.  According to the 2021 National Survey on Drug Use and Health and the National Survey of Substance Abuse Treatment Services, 29.5 million people aged 12 or older had an alcohol use disorder in 2021. 2.6 million of these people received some sort of treatment for their alcohol. Out of these 2.6 million people, 3,81,000 received MAT for AUD. 5.6 million people aged 12 or older had an opioid use disorder in 2021. 1.2 million of these individuals received some sort of treatment for their opioid misuse. Out of these 1.2 million people, 887,000 or nearly 73% received MAT for their opioid misuse. This is expected to boost the methadone market forecast over the coming years.

Increasing government support and initiatives

Supportive policies and funding from governments to combat the opioid crisis enhance the ability and accessibility of methadone treatment programs which is contributing to the growth of the market. For instance, the National Institute of Health (NIH) launched its Helping to End Addiction Long-term Initiative (or NIH HEAL Initiative in 2018 to support science-based solutions to the opioid crisis. As of July 2022, NIH had invested $2 billion in HEAL, funding some 600 research projects nationwide. Similarly, in 2024, The US Department of Health and Human Services’ Health Resources and Services Administration (HRSA) in support of President Biden’s Unity Agenda announced the launch of nearly $50 million for HRSA’s Rural Opioid Treatment and Recovery Initiative and released the initiative's funding application. Funding will support establishing and expanding comprehensive substance use disorder treatment and recovery services in rural areas including by increasing access to medications for opioid use disorder. This is further influencing the methadone market revenue.

Methadone Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on mode of administration, therapeutic area, and distribution channel.

Breakup by Mode of Administration:

• Oral Medicine
• Injections
   

Oral medicine accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the mode of administration. This includes oral medicine and injections. According to the report, oral medicine represented the largest segment.

The demand for oral medicine in the market is driven by its convenience, ease of administration, and patient compliance. Oral formulations allow for precise dosing and are less invasive compared to injectable forms. As methadone is taken by mouth, it gets absorbed through the digestive system easily. The rise in opioid addiction and the need for effective maintenance treatment is further boosting its demand. Increased healthcare provider awareness and patient education about oral methadone benefits, coupled with supportive regulatory frameworks and insurance coverage, enhance its accessibility and acceptance in addiction treatment programs.

Breakup by Therapeutic Area:

• Pain Treatment
• Detoxification
• Maintenance Therapy
   

Pain treatment holds the largest share of the industry

A detailed breakup and analysis of the market based on the therapeutic area have also been provided in the report. This includes pain treatment, detoxification, and maintenance therapy. According to the report, pain treatment accounted for the largest market share.

The effectiveness of methadone in managing chronic pain, especially in patients who are tolerant to other opioids is driving the demand for methadone in pain treatment. Methadone is prescribed by healthcare professionals to manage moderate to severe chronic pain that is not adequately controlled by other pain medications.  Its long duration of action provides sustained pain relief, making it suitable for long-term pain management. Methadone's relatively lower cost compared to other opioids along with its availability in various formulations, enhances its accessibility.

Breakup by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Rehab Centers
• Drug Stores
   

Rehab centers represents the leading market segment 

The report has provided a detailed breakup and analysis of the market based on the distribution channel. This includes hospital pharmacies, retail pharmacies, rehab centers, and drug stores. According to the report, rehab centers represented the largest segment.

The demand for rehab centers in the methadone market is driven by the rising opioid addiction rates, increased awareness of addiction treatment options, and government initiatives promoting rehabilitation. The growing need for effective opioid addiction management, and the availability of methadone as a treatment option, also contributes. Rehab centers provide a holistic approach to addiction treatment by combining medical interventions with counseling, therapy, and support services. They can tailor methadone dosages and treatment plants to the specific needs of each patient which ensures optimal outcomes in the context of substance abuse treatment.

Breakup by Region:

• North America
  • United States
  • Canada
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Others
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

North America leads the market, accounting for the largest methadone market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for methadone.

The increasing prevalence of opioid addiction is driving the market growth across the region. Government agencies in numerous countries including Canada and the USA are undertaking initiatives to expand access to addiction treatment, such as methadone. The growing number of overdose deaths is catalyzing demand for methadone as a life-saving intervention in the region. According to the World Health Organization, in the United States of America, the number of people dying from a drug overdose amounted to 70630 in 2019, and approximately half of these deaths involved synthetic opioids. From 2013 to 2019, the age-adjusted synthetic opioid death rates in the United States increased by 1040%.

Competitive Landscape:

• The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the methadone industry include Mallinckrodt Pharmaceuticals, Hikma Pharmaceuticals PLC, VistaPharm Inc. (Pharmaceutical Associates Inc.), etc.
  
  (Please note that this is only a partial list of the key players, and the complete list is provided in the report.)
   
• The competitive partners methadone market is highly competitive with key players such as Mallinckrodt Pharmaceuticals, Hikma Pharmaceuticals PLC., and VistaPharm Inc. (Pharmaceutical Associates Inc.). These companies focus on product innovation, strategic collaboration, and expansion to maintain market share. Increasing demand for effective opioid connection treatments and chronic pain management fuels competition. For instance, in May 2024, the US pharmacy chain operator Walgreens Boots Alliance launched its brand of popular overdose reversal drug, naloxone, which would be available over the counter. The launch comes a week after Walgreens’ brand was approved by the US Food and Drug Administration in April. Naloxone rapidly reverses or blocks the effects of opioids, restoring normal respiration, especially when given within minutes of the first signs of an overdose.

Methadone Market News:

• In February 2024, Hikma Pharmaceuticals PLC, along with its wholly-owned subsidiary Hikma Pharmaceuticals USA Inc., announced that it has reached an agreement in principle to resolve the vast majority of the opioid-related cases brought against the company by the US states comma their subdivisions comma, and tribal nations.
• In March 2024, the White House launched a nationwide call to action to save lives from opioid overdoses and an election-year effort to tackle the opioid crisis.
• In May 2023, the US Food and Drug Administration approved Opvee, the first nalmefene hydrochloride nasal spray for the emergency treatment of known or suspected opioid overdose in adults and pediatric patients 12 years of age and older. This is the first FDA approval of nalmefene hydrochloride nasal spray for healthcare and community use.

Methadone Market Report Scope:

Key Questions Answered in This Report:

• How has the global methadone market performed so far, and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global methadone market?
• What is the impact of each driver, restraint, and opportunity on the global methadone market?
• What are the key regional markets?
• Which countries represent the most attractive methadone market?
• What is the breakup of the market based on the mode of administration?
• Which is the most attractive mode of administration in the methadone market?
• What is the breakup of the market based on the therapeutic area?
• Which is the most attractive therapeutic area in the methadone market?
• What is the breakup of the market based on the distribution channel?
• Which is the most attractive distribution channel in the methadone market?
• What is the competitive structure of the market?
• Who are the key players/companies in the global methadone market?

Key Benefits for Stakeholders:

• IMARC’s industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the methadone market from 2018-2032.
• The research report provides the latest information on the market drivers, challenges, and opportunities in the global methadone market.
• The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
• Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the methadone industry and its attractiveness.
• The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.